(Q37650580)

21 August 2017

1 reference

title

Clinical safety of ranibizumab in age-related macular degeneration (English)

1 reference

21 August 2017

author

Ursula Schmidt-Erfurth

series ordinal

1

object named as

Ursula Schmidt-Erfurth

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Drug Safety

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

149-165

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

21 August 2017

1 reference

Pathogenesis of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Natural course of poorly defined choroidal neovascularization associated with macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Macular scatter ('grid') laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration. Results of a randomized pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Vascular endothelial growth factor biology: clinical implications for ocular treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Vascular endothelial growth factor gene polymorphisms and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Roles for VEGF in the adult.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Tears of the retinal pigment epithelium: an old problem in a new era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Infectious endophthalmitis after intravitreal injection of antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Retinal pigment epithelial tears in ranibizumab-treated eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Vascular changes after intra-bleb injection of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Cigarette smoking and age-related macular degeneration in the EUREYE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

Hospitalized cardiovascular diseases in neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903418422

10.1517/14740330903418422

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference